CD28 compositions and methods for chimeric antigen receptor therapy
US11535662B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 26, 2018 |
| Grant date | Dec 27, 2022 |
| Priority date | — |
| Expiry date | Jan 15, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein. The CAR may comprise a mutant CD28 costimulatory domain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.